Loading
A phase 3 trial of Radotinib HCl in chronic myeloid leukaemia, run by Il-Yang Pharm. Co., Ltd., now recruiting.
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs is a phase 3 interventional study registered as NCT03459534 by Il-Yang Pharm. Co., Ltd., with 173 participants planned, started 2018-06-25 and due to reach its primary completion in 2027-06-30. Interventions recorded: Radotinib HCl.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Radotinib, Il-Yang Pharmaceutical, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Imatinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/